GlassScriptPhysician profile
Abigail J Eubank
NPI 1588861207
$8,756.28
in general payments reported to CMS, 2019-2025
29 companies · $856 in 2025
The $856 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,448 · 2022: $788 · 2023: $638 · 2024: $1,027 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,984.71 | 2021-2025 | |
| Novo Nordisk INC | $505.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $351.31 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $221.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.90 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $174.87 | 2023-2025 | Mounjaro, Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $165.59 | 2021-2025 | |
| Amgen INC. | $148.84 | 2022-2023 | Evenity, Prolia |
| Abbott Laboratories | $136.12 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Idorsia Pharmaceuticals US INC | $124.65 | 2022-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $105.29 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $102.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.36 | 2021-2023 | Verquvo, Belsomra, Steglujan |
| Corcept Therapeutics | $61.26 | 2025 | Korlym |
| Amarin Pharma, INC. | $57.78 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.56 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $52.81 | 2024 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $38.64 | 2024-2025 | Breztri, Farxiga |
| Shield Therapeutics INC | $33.68 | 2023-2024 | |
| Alkermes, INC. | $26.16 | 2024 | Vivitrol |
| Phathom Pharmaceuticals, INC. | $19.33 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $18.30 | 2024 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $17.35 | 2023 | Sunosi |
| Janssen Pharmaceuticals, INC | $16.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.88 | 2023 | Dupixent |
| Jazz Pharmaceuticals INC. | $14.67 | 2022 | |
| Puma Biotechnology, INC. | $14.35 | 2025 | |
| Tris Pharma INC | $14.08 | 2024 | Dyanavel Xr |
| Alexion Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Eubank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.